The well-worn adage may be “the more things change, the more they stay the same,” but at Melinta Therapeutics Inc., much truly is different. Known until recently as Rib-X Pharmaceuticals, the 13-year-old antibiotic specialist is moving forward with a new name and management team, has regained full rights to a class of novel antibiotics, and has revised its Phase III program for lead candidate delafloxacin.
In a series of announcements Oct. 7, the New Haven, Conn., biotech unveiled its revised strategy and hired former Pearl Therapeutics Inc. executive Lyn Baranowski as senior VP of corporate development and strategy